The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.
 
Veronica Conca
No Relationships to Disclose
 
Roberto Moretto
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Carlotta Antoniotti
Honoraria - Merck
Travel, Accommodations, Expenses - Merck
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi-Sankyo; Ipsen; Johnson&Johnson; Merck Serono; MSD Oncology; Pierre Fabre; Rottapharm Biotech; Seagen; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BMS; Daiichi-Sankyo; Gilead Sciences; GlaxoSmithKline; Incyte; Jazz Pharmaceuticals,; Johnson & Johnson/Janssen; Merck Serono; MSD Oncology; Pfizer; Pierre Fabre; Rottapharm Biotech; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Rottapharm Biotech (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre; Takeda Science Foundation
 
Federica Marmorino
No Relationships to Disclose
 
Lorenzo Antonuzzo
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Consulting or Advisory Role - Merck Serono; MSD Oncology
 
Beatrice Borelli
Honoraria - TERUMO
Consulting or Advisory Role - TERUMO
Travel, Accommodations, Expenses - Merck Serono; SERVIER
 
Eleonora Perissinotto
No Relationships to Disclose
 
Giovanni Randon
Honoraria - Accademia Nazionale Di Medicina (ACCMED)
 
Marco Maria Germani
No Relationships to Disclose
 
Ilaria Toma
No Relationships to Disclose
 
Francesco Sullo
No Relationships to Disclose
 
Gianluca Masi
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology; Roche; Roche; TERUMO
Research Funding - Terumo (Inst); Terumo (Inst)
Patents, Royalties, Other Intellectual Property - Terumo (Inst)
 
Carmelo Pozzo
Consulting or Advisory Role - Amgen; Lilly; SERVIER
 
Cristina Morelli
No Relationships to Disclose
 
Angela Buonadonna
No Relationships to Disclose
 
Luca Boni
Consulting or Advisory Role - Pfizer
Patents, Royalties, Other Intellectual Property - International Patent nr. PCT/EP2012/065661
 
Daniele Rossini
Speakers' Bureau - Amgen; Bayer; MSD; Pierre Fabre; Takeda
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER